PURPOSE: Although gene expression profiling is a promising diagnostic technique to determine the tissue of origin for patients with cancer of unknown primary site (CUP), no clinical trial has evaluated yet site-specific therapy directed by this approach compared with empirical chemotherapy. We therefore performed a randomized study to assess whether such site-specific therapy improves outcome compared with empirical chemotherapy in previously untreated patients with CUP. PATIENTS AND METHODS: Comprehensive gene expression profiling was performed by microarray analysis, and an established algorithm was applied to predict tumor origin. Patients with CUP were randomly assigned (1:1) to receive standard site-specific therapy or empirical paclitaxel and carboplatin (PC). The primary end point was 1-year survival rate. RESULTS:One hundred thirty patients were randomly assigned and had sufficient biopsy tissue for molecular analysis. Efficacy analysis was performed for 50 and 51 patients in the site-specific therapy and empirical PC arms, respectively. Cancer types most commonly predicted were pancreatic (21%), gastric (21%), and lymphoma (20%). The 1-year survival rate was 44.0% and 54.9% for site-specific treatment and empirical PC ( P = .264), respectively. Median overall and progression-free survival were 9.8 and 5.1 months, respectively, for site-specific treatment versus 12.5 and 4.8 months for empirical PC ( P = .896 and .550, respectively). Median overall survival (16.7 v 10.6 months; P = .116) and progression-free survival (5.5 v 3.9 months; P = .018) were better for predicted more-responsive than less-responsive tumor types. CONCLUSION: Site-specific treatment that was based on microarray profiling did not result in a significant improvement in 1-year survival compared with empirical PC, although prediction of the original site seemed to be of prognostic value.
RCT Entities:
PURPOSE: Although gene expression profiling is a promising diagnostic technique to determine the tissue of origin for patients with cancer of unknown primary site (CUP), no clinical trial has evaluated yet site-specific therapy directed by this approach compared with empirical chemotherapy. We therefore performed a randomized study to assess whether such site-specific therapy improves outcome compared with empirical chemotherapy in previously untreated patients with CUP. PATIENTS AND METHODS: Comprehensive gene expression profiling was performed by microarray analysis, and an established algorithm was applied to predict tumor origin. Patients with CUP were randomly assigned (1:1) to receive standard site-specific therapy or empirical paclitaxel and carboplatin (PC). The primary end point was 1-year survival rate. RESULTS: One hundred thirty patients were randomly assigned and had sufficient biopsy tissue for molecular analysis. Efficacy analysis was performed for 50 and 51 patients in the site-specific therapy and empirical PC arms, respectively. Cancer types most commonly predicted were pancreatic (21%), gastric (21%), and lymphoma (20%). The 1-year survival rate was 44.0% and 54.9% for site-specific treatment and empirical PC ( P = .264), respectively. Median overall and progression-free survival were 9.8 and 5.1 months, respectively, for site-specific treatment versus 12.5 and 4.8 months for empirical PC ( P = .896 and .550, respectively). Median overall survival (16.7 v 10.6 months; P = .116) and progression-free survival (5.5 v 3.9 months; P = .018) were better for predicted more-responsive than less-responsive tumor types. CONCLUSION: Site-specific treatment that was based on microarray profiling did not result in a significant improvement in 1-year survival compared with empirical PC, although prediction of the original site seemed to be of prognostic value.
Authors: Sungmin Woo; Anton S Becker; Richard K G Do; Heiko Schöder; Hedvig Hricak; H Alberto Vargas Journal: Eur J Cancer Date: 2021-11-02 Impact factor: 9.162
Authors: Kanwal Raghav; Hyunsoo Hwang; Alexandre A Jácome; Eric Bhang; Anneleis Willett; Ryan W Huey; Nishat P Dhillon; Jignesh Modha; Brandon Smaglo; Aurelio Matamoros; Jeannelyn S Estrella; Justin Jao; Michael J Overman; Xuemei Wang; F Anthony Greco; Jonathan M Loree; Gauri R Varadhachary Journal: Clin Cancer Res Date: 2021-04-15 Impact factor: 12.531
Authors: Holger Moch; Alwin Krämer; Chantal Pauli; Tilmann Bochtler; Linda Mileshkin; Giulia Baciarello; Ferran Losa; Jeffrey S Ross; George Pentheroudakis; George Zarkavelis; Suayib Yalcin; Mustafa Özgüroğlu; Andreas Beringer; Jeremy Scarato; Mathis Mueller-Ohldach; Marlene Thomas Journal: Oncologist Date: 2021-03-25
Authors: Silvia Benvenuti; Melissa Milan; Elena Geuna; Alberto Pisacane; Rebecca Senetta; Gennaro Gambardella; Giulia M Stella; Filippo Montemurro; Anna Sapino; Carla Boccaccio; Paolo M Comoglio Journal: EMBO Mol Med Date: 2020-06-08 Impact factor: 12.137